You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlunarizine
Accession NumberDB04841
TypeSmall Molecule
GroupsApproved
DescriptionFlunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Structure
Thumb
Synonyms
1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
Flunarizina
Flunarizinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Flunarizinecapsule5 mgoralAa Pharma Inc2002-08-08Not applicableCanada
Novo-flunarizine - Cap 5mgcapsule5 mgoralNovopharm Limited1998-04-302015-10-26Canada
Sibelium Cap 5mgcapsule5 mgoralPharmascience Inc1990-12-312009-01-29Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FlugeralItalfarmaco
FluxartenGlaxoSmithKline
GradientPolifarma
SibeliumJanssen
ZinasenAtralCipan
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flunarizine dihydrochloride
Thumb
  • InChI Key: RXKMOPXNWTYEHI-RDRKJGRWSA-N
  • Monoisotopic Mass: 476.15976073
  • Average Mass: 477.417
DBSALT000382
Categories
UNIIR7PLA2DM0J
CAS number52468-60-7
WeightAverage: 404.4948
Monoisotopic: 404.206405252
Chemical FormulaC26H26F2N2
InChI KeyInChIKey=SMANXXCATUTDDT-QPJJXVBHSA-N
InChI
InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
IUPAC Name
1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
SMILES
FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropene
  • Styrene
  • Aralkylamine
  • N-alkylpiperazine
  • Halobenzene
  • Fluorobenzene
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl fluoride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
PharmacodynamicsFlunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity.
Mechanism of actionFlunarizine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Related Articles
Absorption85% following oral administration.
Volume of distributionNot Available
Protein binding99% bound to plasma proteins
Metabolism

Hepatic, to two metabolites via N-dealylation and hydroxylation.

SubstrateEnzymesProduct
Flunarizine
Flunarizine metabolite M1Details
Flunarizine
Flunarizine metabolite M2Details
Flunarizine
Flunarizine metabolite M3Details
Route of eliminationNot Available
Half life18 days
ClearanceNot Available
Toxicity-Flunarizine should be used with care in patients with depression or those being prescribed other agents, such as phenothiazines, concurrently, which may cause extrapyramidal side-effects. -Acute overdosage has been reported and the observed symptoms were sedation, agitation and tachycardia. -Treatment of acute overdosage consists of charcoal administration, induction of emesis or gastric lavage, and supportive measures. No specific antidote is known.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9574
Blood Brain Barrier+0.9789
Caco-2 permeable+0.5893
P-glycoprotein substrateSubstrate0.7209
P-glycoprotein inhibitor IInhibitor0.9266
P-glycoprotein inhibitor IINon-inhibitor0.6563
Renal organic cation transporterInhibitor0.7605
CYP450 2C9 substrateNon-substrate0.8855
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.7208
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9229
CYP450 2D6 inhibitorInhibitor0.9323
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9034
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7304
Ames testNon AMES toxic0.8902
CarcinogenicityNon-carcinogens0.9422
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3271 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5261
hERG inhibition (predictor II)Inhibitor0.7549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral5 mg
Prices
Unit descriptionCostUnit
Apo-Flunarizine 5 mg Capsule0.75USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point251.5Janssen, P.A.J.; U.S. Patent 3,773,939; November 20, 1973; assigned to Janssen Pharmaceutica N.V.
logP5.78BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00168 mg/mLALOGPS
logP5.3ALOGPS
logP6.17ChemAxon
logS-5.4ALOGPS
pKa (Strongest Basic)7.6ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity120.3 m3·mol-1ChemAxon
Polarizability44.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Matthew Peterson, Julius Remenar, Carlos Sanrame, “NOVEL FLUNARIZINE SALT FORMS AND METHODS OF MAKING AND USING THE SAME.” U.S. Patent US20080200474, issued August 21, 2008.

US20080200474
General ReferencesNot Available
External Links
ATC CodesN07CA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Flunarizine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Flunarizine.
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Flunarizine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Flunarizine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Flunarizine.
AbirateroneThe serum concentration of Flunarizine can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Flunarizine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Flunarizine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Flunarizine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Flunarizine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Flunarizine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Flunarizine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Flunarizine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Flunarizine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flunarizine.
AmiodaroneThe metabolism of Flunarizine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Flunarizine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flunarizine.
AmobarbitalThe metabolism of Flunarizine can be increased when combined with Amobarbital.
AmobarbitalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Amobarbital.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Flunarizine.
AmoxapineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Flunarizine.
AmphetamineAmphetamine may decrease the sedative activities of Flunarizine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Flunarizine.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Flunarizine.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Flunarizine.
AprepitantThe metabolism of Flunarizine can be increased when combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunarizine.
ArtemetherThe metabolism of Flunarizine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Flunarizine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Flunarizine.
AtomoxetineThe metabolism of Flunarizine can be decreased when combined with Atomoxetine.
AtosibanThe risk or severity of adverse effects can be increased when Flunarizine is combined with Atosiban.
Atracurium besylateFlunarizine may increase the neuromuscular blocking activities of Atracurium besylate.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Flunarizine.
AzelastineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunarizine.
AzithromycinThe metabolism of Flunarizine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Flunarizine.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Flunarizine.
BarbitalThe metabolism of Flunarizine can be increased when combined with Barbital.
BarbitalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Flunarizine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Flunarizine.
BenzphetamineBenzphetamine may decrease the sedative activities of Flunarizine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Flunarizine.
Benzylpenicilloyl PolylysineFlunarizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Flunarizine.
BetaxololThe metabolism of Flunarizine can be decreased when combined with Betaxolol.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Flunarizine.
BortezomibThe metabolism of Flunarizine can be decreased when combined with Bortezomib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flunarizine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
BrimonidineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flunarizine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Flunarizine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Flunarizine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flunarizine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Flunarizine.
BupropionThe metabolism of Flunarizine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flunarizine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flunarizine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Flunarizine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Flunarizine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Flunarizine.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Flunarizine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Flunarizine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Flunarizine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flunarizine.
CaffeineThe metabolism of Flunarizine can be decreased when combined with Caffeine.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Flunarizine.
CapecitabineThe metabolism of Flunarizine can be decreased when combined with Capecitabine.
CarbamazepineThe serum concentration of Flunarizine can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Flunarizine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Flunarizine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flunarizine.
CarvedilolCarvedilol may increase the hypotensive activities of Flunarizine.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Flunarizine.
CelecoxibThe metabolism of Flunarizine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Flunarizine can be increased when it is combined with Ceritinib.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Flunarizine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Flunarizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Flunarizine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flunarizine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Flunarizine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flunarizine.
ChloroquineThe metabolism of Flunarizine can be decreased when combined with Chloroquine.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Flunarizine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flunarizine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Flunarizine.
ChlorpromazineThe metabolism of Flunarizine can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flunarizine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Flunarizine.
CholecalciferolThe metabolism of Flunarizine can be decreased when combined with Cholecalciferol.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Flunarizine.
CimetidineThe metabolism of Flunarizine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Flunarizine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flunarizine.
CitalopramThe risk or severity of adverse effects can be increased when Flunarizine is combined with Citalopram.
CitalopramThe metabolism of Flunarizine can be decreased when combined with Citalopram.
ClemastineThe metabolism of Flunarizine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Flunarizine.
ClobazamThe metabolism of Flunarizine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Flunarizine.
ClomipramineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clomipramine.
ClomipramineThe metabolism of Flunarizine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Flunarizine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flunarizine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Flunarizine.
ClopidogrelThe metabolism of Flunarizine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flunarizine.
ClotrimazoleThe metabolism of Flunarizine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Flunarizine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clozapine.
CobicistatThe serum concentration of Flunarizine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Flunarizine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flunarizine.
CrizotinibThe metabolism of Flunarizine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Flunarizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunarizine.
CyclosporineThe metabolism of Flunarizine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Flunarizine.
Cyproterone acetateThe serum concentration of Flunarizine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Flunarizine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flunarizine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flunarizine.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Flunarizine.
DapoxetineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dapoxetine.
DarifenacinThe metabolism of Flunarizine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Flunarizine can be increased when it is combined with Darunavir.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Flunarizine.
DeferasiroxThe serum concentration of Flunarizine can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Flunarizine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Flunarizine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Flunarizine.
DesipramineThe metabolism of Flunarizine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flunarizine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Flunarizine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunarizine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flunarizine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Flunarizine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Flunarizine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flunarizine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Flunarizine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flunarizine.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Flunarizine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flunarizine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flunarizine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Flunarizine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flunarizine.
DiphenhydramineThe metabolism of Flunarizine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flunarizine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Flunarizine.
DoxazosinDoxazosin may increase the hypotensive activities of Flunarizine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Flunarizine.
DoxorubicinThe metabolism of Flunarizine can be decreased when combined with Doxorubicin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
DoxylamineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Flunarizine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
DronedaroneThe metabolism of Flunarizine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Flunarizine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Flunarizine.
DuloxetineThe metabolism of Flunarizine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flunarizine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Flunarizine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Flunarizine.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Flunarizine.
EfavirenzThe serum concentration of Flunarizine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Flunarizine is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Flunarizine.
EliglustatThe metabolism of Flunarizine can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Flunarizine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Flunarizine.
EscitalopramThe risk or severity of adverse effects can be increased when Flunarizine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Flunarizine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flunarizine.
EthanolFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Flunarizine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunarizine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flunarizine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flunarizine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Flunarizine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Flunarizine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flunarizine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Flunarizine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Flunarizine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Flunarizine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Flunarizine.
EtoperidoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Flunarizine.
EtravirineThe metabolism of Flunarizine can be decreased when combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Flunarizine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flunarizine.
FenfluramineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flunarizine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Flunarizine.
FlibanserinThe risk or severity of adverse effects can be increased when Flunarizine is combined with Flibanserin.
FloxuridineThe metabolism of Flunarizine can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of Flunarizine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Flunarizine.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Flunarizine.
FluorouracilThe metabolism of Flunarizine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fluoxetine.
FluoxetineThe metabolism of Flunarizine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flunarizine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flunarizine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flunarizine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Flunarizine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Flunarizine.
FluvastatinThe metabolism of Flunarizine can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Flunarizine can be decreased when combined with Fluvoxamine.
FosphenytoinThe serum concentration of Flunarizine can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Flunarizine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flunarizine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Flunarizine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Flunarizine.
GemfibrozilThe metabolism of Flunarizine can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Flunarizine.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Flunarizine.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Flunarizine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flunarizine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Flunarizine.
HaloperidolThe metabolism of Flunarizine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Haloperidol.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Flunarizine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Flunarizine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Flunarizine.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Flunarizine.
HexobarbitalThe metabolism of Flunarizine can be increased when combined with Hexobarbital.
HexobarbitalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Hexobarbital.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flunarizine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Flunarizine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunarizine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Flunarizine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
HydroxyzineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Iloperidone.
ImipramineThe metabolism of Flunarizine can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Indalpine.
IndinavirThe metabolism of Flunarizine can be decreased when combined with Indinavir.
IndoraminIndoramin may increase the hypotensive activities of Flunarizine.
IrbesartanThe metabolism of Flunarizine can be decreased when combined with Irbesartan.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Flunarizine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Flunarizine.
IsoniazidThe metabolism of Flunarizine can be decreased when combined with Isoniazid.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Flunarizine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Flunarizine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flunarizine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Flunarizine.
KetoconazoleThe metabolism of Flunarizine can be decreased when combined with Ketoconazole.
LabetalolLabetalol may increase the hypotensive activities of Flunarizine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flunarizine.
LeflunomideThe metabolism of Flunarizine can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flunarizine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Flunarizine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Flunarizine.
LevocetirizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Flunarizine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flunarizine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flunarizine.
LidocaineThe metabolism of Flunarizine can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Lidocaine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Flunarizine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Flunarizine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Flunarizine.
LopinavirThe metabolism of Flunarizine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Flunarizine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flunarizine.
LorcaserinThe metabolism of Flunarizine can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Flunarizine can be decreased when combined with Losartan.
LovastatinThe metabolism of Flunarizine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flunarizine.
Lu AA21004The risk or severity of adverse effects can be increased when Flunarizine is combined with Lu AA21004.
LumacaftorThe serum concentration of Flunarizine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Flunarizine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Flunarizine.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium salicylate.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flunarizine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Flunarizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Flunarizine.
MefloquineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Flunarizine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Flunarizine.
MephentermineMephentermine may decrease the sedative activities of Flunarizine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flunarizine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flunarizine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flunarizine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flunarizine.
MethadoneThe metabolism of Flunarizine can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Flunarizine.
MethamphetamineMethamphetamine may decrease the sedative activities of Flunarizine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Flunarizine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Flunarizine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flunarizine.
MethohexitalThe metabolism of Flunarizine can be increased when combined with Methohexital.
MethohexitalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Flunarizine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flunarizine.
MethsuximideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methsuximide.
MethylphenobarbitalThe metabolism of Flunarizine can be increased when combined with Methylphenobarbital.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methylphenobarbital.
MetoprololThe metabolism of Flunarizine can be decreased when combined with Metoprolol.
MetyrosineFlunarizine may increase the sedative activities of Metyrosine.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Flunarizine.
MexiletineThe metabolism of Flunarizine can be decreased when combined with Mexiletine.
MianserinThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Mianserin.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Flunarizine.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Flunarizine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flunarizine.
MifepristoneThe serum concentration of Flunarizine can be increased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Flunarizine is combined with Milnacipran.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Flunarizine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
MirabegronThe metabolism of Flunarizine can be decreased when combined with Mirabegron.
MirtazapineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flunarizine.
MivacuriumFlunarizine may increase the neuromuscular blocking activities of Mivacurium.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Flunarizine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Flunarizine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Flunarizine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Flunarizine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
NabiloneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Nabilone.
NafcillinThe metabolism of Flunarizine can be increased when combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Flunarizine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flunarizine.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Flunarizine.
NevirapineThe metabolism of Flunarizine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Flunarizine can be decreased when combined with Nicardipine.
NicotineThe metabolism of Flunarizine can be decreased when combined with Nicotine.
NilotinibThe metabolism of Flunarizine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flunarizine.
NitroprussideFlunarizine may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Flunarizine.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Flunarizine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Flunarizine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flunarizine.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Flunarizine.
OlanzapineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunarizine.
OmeprazoleThe metabolism of Flunarizine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flunarizine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Flunarizine.
OrlistatThe serum concentration of Flunarizine can be decreased when it is combined with Orlistat.
OrphenadrineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flunarizine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Flunarizine.
OsimertinibThe serum concentration of Flunarizine can be decreased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flunarizine.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Flunarizine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Flunarizine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Flunarizine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flunarizine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flunarizine.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Flunarizine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flunarizine.
PanobinostatThe metabolism of Flunarizine can be decreased when combined with Panobinostat.
ParaldehydeFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Flunarizine.
ParoxetineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Paroxetine.
ParoxetineThe metabolism of Flunarizine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Flunarizine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Flunarizine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flunarizine.
PentobarbitalThe metabolism of Flunarizine can be increased when combined with Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Flunarizine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Flunarizine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flunarizine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flunarizine.
PhenobarbitalThe metabolism of Flunarizine can be increased when combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Flunarizine.
PhenterminePhentermine may decrease the sedative activities of Flunarizine.
PhenytoinThe serum concentration of Flunarizine can be decreased when it is combined with Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Flunarizine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Flunarizine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Flunarizine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flunarizine.
PizotifenThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pomalidomide.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Flunarizine.
PramipexoleFlunarizine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Flunarizine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Flunarizine.
PrazosinPrazosin may increase the hypotensive activities of Flunarizine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flunarizine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Flunarizine.
PrimidoneThe metabolism of Flunarizine can be increased when combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Flunarizine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunarizine.
PromazineThe metabolism of Flunarizine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Flunarizine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flunarizine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Flunarizine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Flunarizine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flunarizine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Flunarizine.
PyrimethamineThe metabolism of Flunarizine can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Flunarizine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunarizine.
QuinidineThe metabolism of Flunarizine can be decreased when combined with Quinidine.
QuinineThe metabolism of Flunarizine can be decreased when combined with Quinine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Flunarizine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Flunarizine.
RanolazineThe metabolism of Flunarizine can be decreased when combined with Ranolazine.
RapacuroniumFlunarizine may increase the neuromuscular blocking activities of Rapacuronium.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flunarizine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flunarizine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flunarizine.
RifampicinThe metabolism of Flunarizine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Flunarizine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Flunarizine.
RitonavirThe metabolism of Flunarizine can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Flunarizine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Flunarizine.
RopiniroleFlunarizine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Flunarizine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunarizine.
RotigotineFlunarizine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flunarizine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Flunarizine.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Flunarizine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flunarizine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flunarizine.
SecobarbitalThe metabolism of Flunarizine can be increased when combined with Secobarbital.
SecobarbitalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Secobarbital.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Flunarizine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Flunarizine.
SertralineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Sertraline.
SertralineThe metabolism of Flunarizine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flunarizine.
SildenafilThe metabolism of Flunarizine can be decreased when combined with Sildenafil.
SilodosinSilodosin may increase the hypotensive activities of Flunarizine.
SimeprevirThe metabolism of Flunarizine can be decreased when combined with Simeprevir.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Flunarizine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Flunarizine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Flunarizine.
SorafenibThe metabolism of Flunarizine can be decreased when combined with Sorafenib.
StiripentolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flunarizine.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Flunarizine.
SulfadiazineThe metabolism of Flunarizine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Flunarizine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Flunarizine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flunarizine.
SuvorexantThe risk or severity of adverse effects can be increased when Flunarizine is combined with Suvorexant.
TamsulosinTamsulosin may increase the hypotensive activities of Flunarizine.
TapentadolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tasimelteon.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Flunarizine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flunarizine.
TenofovirThe metabolism of Flunarizine can be decreased when combined with Tenofovir.
TerazosinTerazosin may increase the hypotensive activities of Flunarizine.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Flunarizine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Flunarizine.
TeriflunomideThe serum concentration of Flunarizine can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Flunarizine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Flunarizine.
ThalidomideFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flunarizine.
TheophyllineThe metabolism of Flunarizine can be decreased when combined with Theophylline.
ThiamylalThe metabolism of Flunarizine can be increased when combined with Thiamylal.
ThiamylalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Thiamylal.
ThiopentalThe metabolism of Flunarizine can be increased when combined with Thiopental.
ThiopentalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flunarizine.
ThiotepaThe metabolism of Flunarizine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flunarizine.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Flunarizine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Flunarizine.
TicagrelorThe metabolism of Flunarizine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Flunarizine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Flunarizine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Flunarizine.
TipranavirThe metabolism of Flunarizine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flunarizine.
TolbutamideThe metabolism of Flunarizine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flunarizine.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Flunarizine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Flunarizine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flunarizine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Flunarizine.
TranylcypromineThe metabolism of Flunarizine can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Flunarizine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunarizine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flunarizine.
TrimazosinTrimazosin may increase the hypotensive activities of Flunarizine.
TrimethoprimThe metabolism of Flunarizine can be decreased when combined with Trimethoprim.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Flunarizine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flunarizine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Flunarizine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Flunarizine.
ValsartanThe metabolism of Flunarizine can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Flunarizine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Flunarizine can be decreased when combined with Venlafaxine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Flunarizine.
VilazodoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Vilazodone.
VoriconazoleThe metabolism of Flunarizine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Flunarizine.
ZafirlukastThe metabolism of Flunarizine can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flunarizine.
ZiconotideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Zimelidine.
ZiprasidoneThe metabolism of Flunarizine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Flunarizine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flunarizine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flunarizine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Flunarizine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Flunarizine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flunarizine.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1G
Uniprot ID:
O43497
Molecular Weight:
262468.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ: Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. doi: 10.1007/s12013-009-9057-4. Epub 2009 Jul 7. [PubMed:19582593 ]
  4. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, Snutch TP: Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. [PubMed:11784784 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ: Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. doi: 10.1007/s12013-009-9057-4. Epub 2009 Jul 7. [PubMed:19582593 ]
  5. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, Snutch TP: Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. [PubMed:11784784 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. Isoform alpha-1I gives rise to T-type calcium currents. T-type calcium channels belong to the "low-volta...
Gene Name:
CACNA1I
Uniprot ID:
Q9P0X4
Molecular Weight:
245100.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ: Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. doi: 10.1007/s12013-009-9057-4. Epub 2009 Jul 7. [PubMed:19582593 ]
  4. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, Snutch TP: Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. [PubMed:11784784 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Taylor JE, Defeudis FV: Interactions of verapamil, D 600, flunarizine and nifedipine with cerebral histamine-receptors. Neurochem Int. 1986;9(3):379-81. [PubMed:20493137 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on September 27, 2007 07:47 / Updated on August 17, 2016 12:24